Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ralgex sticks
1003020N0BLACA0
|
Ralgex Heat Spray/Stick | Methyl salicylate | Musculoskeletal and Joint Diseases | No data available |
|
Rasburicase 1.5mg inf vials
1001040U0AAAAAA
|
Rasburicase | Rasburicase | Musculoskeletal and Joint Diseases | No data available |
|
Rasburicase 7.5mg inf vials
1001040U0AAABAB
|
Rasburicase | Rasburicase | Musculoskeletal and Joint Diseases | No data available |
|
Relcofen 400mg tablets
1001010J0BYABAE
|
Relcofen | Ibuprofen | Musculoskeletal and Joint Diseases | No data available |
|
Relifex 500mg dispersible tablets
1001010X0BBACAC
|
Relifex | Nabumetone | Musculoskeletal and Joint Diseases | No data available |
|
Remicade 100mg pdr for concentrate for inf vials
1001030T0BBAAAA
|
Remicade | Infliximab | Musculoskeletal and Joint Diseases | No data available |
|
Remsima 100mg pdr for concentrate for inf vials
1001030T0BCAAAA
|
Remsima | Infliximab | Musculoskeletal and Joint Diseases | No data available |
|
Remsima 120mg/1ml solution for injection pre-filled pens
1001030T0BCABAB
|
Remsima | Infliximab | Musculoskeletal and Joint Diseases | No data available |
|
Remsima 120mg/1ml solution for injection pre-filled syringes
1001030T0BCACAC
|
Remsima | Infliximab | Musculoskeletal and Joint Diseases | No data available |
|
Rheumacin LA 75mg capsules
1001010K0BKAAAD
|
Rheumacin LA | Indometacin | Musculoskeletal and Joint Diseases | No data available |
|
Rheumatac Retard 75 tablets
1001010C0CEAAAL
|
Rheumatac | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Rheumox 300mg capsules
1001010B0BBAAAA
|
Rheumox | Azapropazone | Musculoskeletal and Joint Diseases | No data available |
|
Rheumox 600mg tablets
1001010B0BBABAB
|
Rheumox | Azapropazone | Musculoskeletal and Joint Diseases | No data available |
|
Rhumalgan CR 100 tablets
1001010C0BDADAF
|
Rhumalgan | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Rhumalgan CR 75 tablets
1001010C0BDACAL
|
Rhumalgan | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Rhumalgan SR 75mg capsules (Actavis)
1001010C0BDAIAW
|
Rhumalgan | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Rhumalgan SR 75mg capsules (Almus)
1001010C0BDAGAW
|
Rhumalgan | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Rhumalgan SR 75mg capsules (Sandoz Ltd)
1001010C0BDAFAW
|
Rhumalgan | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Rhumalgan XL 100mg capsules (Actavis)
1001010C0BDAJAN
|
Rhumalgan | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Rhumalgan XL 100mg capsules (Almus)
1001010C0BDAHAN
|
Rhumalgan | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Rhumalgan XL 100mg capsules (Sandoz)
1001010C0BDAEAN
|
Rhumalgan | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Ridaura Tiltab 3mg tablets
1001030A0BBAAAA
|
Ridaura | Auranofin | Musculoskeletal and Joint Diseases | No data available |
|
Rinvoq 15mg modified-release tablets
1001030AEBBAAAA
|
Rinvoq | Upadacitinib | Musculoskeletal and Joint Diseases | No data available |
|
Rinvoq 30mg modified-release tablets
1001030AEBBABAB
|
Rinvoq | Upadacitinib | Musculoskeletal and Joint Diseases | No data available |
|
Rinvoq 45mg modified-release tablets
1001030AEBBACAC
|
Rinvoq | Upadacitinib | Musculoskeletal and Joint Diseases | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.